MedWatch

CSL eyeing acquisition candidate in Vifor Pharma

An Australian media has indicated that CSL is in talks to acquire Swiss Vifor Pharma, a competitor to Pharmacosmos, which is based in Denmark.

Photo: Vifor Pharma / PR

The Swiss specialty pharmaceuticals company, Vifor Pharma, is up 15.6 percent at CHF 120 (USD 130,4) following news that Australian CSL wants to take over the Swiss firm, writes Bloomberg News, citing Australian Financial Reviews.

CSL has tasked Bank of America with advising the purchase, including the possibility of raising capital of AUD 4bn (USD 2.8bn) from investors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs